These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 35413880)

  • 1. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.
    Wu J; Liu T; Shi S; Fan Z; Hiram R; Xiong F; Cui B; Su X; Chang R; Zhang W; Yan M; Tang Y; Huang H; Wu G; Huang C
    Cardiovasc Diabetol; 2022 Sep; 21(1):197. PubMed ID: 36171554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
    Chowdhury B; Luu AZ; Luu VZ; Kabir MG; Pan Y; Teoh H; Quan A; Sabongui S; Al-Omran M; Bhatt DL; Mazer CD; Connelly KA; Verma S; Hess DA
    Biochem Biophys Res Commun; 2020 Mar; 524(1):50-56. PubMed ID: 31980166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gα11 expression and effect of sildenafil in muscularization of non-muscular pulmonary arterioles in rat with pulmonary arterial hypertension].
    Huang SA; Luo P; Wu YC; He JG; Chen C; Lei W
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1762-5. PubMed ID: 27356645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline.
    Qin T; Kong B; Dai C; Xiao Z; Fang J; Shuai W; Huang H
    Bioengineered; 2022 Feb; 13(2):2697-2709. PubMed ID: 35042435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
    Huang W; Zhou H; He Y; Wang A; Wang B; Chen Y; Liu C; Wang H; Xie W; Kong H
    Exp Cell Res; 2024 Aug; 441(1):114154. PubMed ID: 38996959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
    Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
    Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
    Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
    Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
    Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
    Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
    BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension.
    Felix NS; de Mendonça L; Braga CL; da Silva JS; Samary CDS; Vieira JB; Cruz F; Rocha NN; Zapata-Sudo G; Rocco PRM; Silva PL
    Br J Pharmacol; 2019 Dec; 176(23):4462-4473. PubMed ID: 31351013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats.
    Kuang T; Wang J; Pang B; Huang X; Burg ED; Yuan JX; Wang C
    Pulm Pharmacol Ther; 2010 Oct; 23(5):456-64. PubMed ID: 20188205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
    Liu J; Fang G; Lan C; Qiu C; Yao L; Zhang Q; Hu J; Zhang Y; Yang Y; Zhang Y
    Drug Des Devel Ther; 2024; 18():767-780. PubMed ID: 38495631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
    Jasińska-Stroschein M; Owczarek J; Łuczak A; Orszulak-Michalak D
    Pharmacology; 2013; 91(3-4):178-84. PubMed ID: 23428587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced pluripotent stem cell-derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2.
    Chi PL; Cheng CC; Wang MT; Liao JB; Kuo SH; Lin KC; Shen MC; Huang WC
    Cardiovasc Res; 2024 Mar; 120(2):203-214. PubMed ID: 38252891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
    Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of aqueous extract of stem bark of Terminalia arjuna (Roxb.), An ayurvedic drug in experimental pulmonary hypertension.
    Meghwani H; Prabhakar P; Mohammed SA; Seth S; Hote MP; Banerjee SK; Arava S; Ray R; Maulik SK
    J Ethnopharmacol; 2017 Feb; 197():184-194. PubMed ID: 27401289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.